Blood Lymphocyte Subsets Identify Optimal Responders to IFN-beta in MS

Overview

Journal J Neurol

Specialty Neurology

Date 2017 Oct 14

PMID 29027004

Citations 4

Authors

Raquel Alenda

Lucienne Costa-Frossard

Roberto Alvarez-Lafuente

Carmen Espejo

Eulalia Rodriguez-Martin

Susana Sainz De La Maza

Noelia Villarrubia

Jordi Rio

Maria I Dominguez-Mozo

Xavier Montalban

Jose C Alvarez-Cermeno

Luisa M Villar

Affiliations

Soon will be listed here.

Abstract

Response to interferon-beta (IFN-beta) treatment is heterogeneous in multiple sclerosis (MS). We aimed to search for biomarkers predicting no evidence of disease activity (NEDA) status upon IFN-beta treatment in MS. 119 patients with relapsing-remitting MS (RRMS) initiating IFN-beta treatment were included in the study, and followed prospectively for 2 years. Neutralizing antibodies (NAb) were explored in serum samples obtained after 6 and 12 months of IFN-beta treatment. Soluble cytokines and blood lymphocytes were studied in basal samples by ELISA and flow cytometry, respectively. 9% of patients developed NAb. These antibodies were more frequent in patients receiving IFN-beta 1b than in those treated subcutaneous (p = 0.008) or intramuscular (p < 0.0001) IFN-beta 1a. No patient showing NAb remained NEDA during follow-up. Basal immunological variables are also associated with patient response. Percentages below 3% of CD19 + CD5 + cells (AUC 0.74, CI 0.63-0.84; OR 10.68, CI 3.55-32.15, p < 0.0001; Likelihood ratio 4.28) or above 2.6% of CD8 + perforin + T cells (AUC 0.79, CI 0.63-0.96; OR 6.11, CI 2.0-18.6, p = 0.0009; Likelihood ratio 5.47) increased the probability of achieving NEDA status during treatment. Basal blood immune cell subsets contribute to identify MS patients with a high probability of showing an optimal response to IFN-beta.

Citing Articles

Peripheral myeloid-derived suppressor cells are good biomarkers of the efficacy of fingolimod in multiple sclerosis.

Camacho-Toledano C, Machin-Diaz I, Calahorra L, Cabanas-Cotillas M, Otaegui D, Castillo-Trivino T J Neuroinflammation. 2022; 19(1):277.

PMID: 36403026 PMC: 9675277. DOI: 10.1186/s12974-022-02635-3.

Role of B Cell Profile for Predicting Secondary Autoimmunity in Patients Treated With Alemtuzumab.

Walo-Delgado P, Monreal E, Medina S, Quintana E, Sainz De La Maza S, Fernandez-Velasco J Front Immunol. 2021; 12:760546.

PMID: 34691084 PMC: 8531491. DOI: 10.3389/fimmu.2021.760546.

Herpesvirus Antibodies, Vitamin D and Short-Chain Fatty Acids: Their Correlation with Cell Subsets in Multiple Sclerosis Patients and Healthy Controls.

Dominguez-Mozo M, Perez-Perez S, Villarrubia N, Costa-Frossard L, Fernandez-Velasco J, Ortega-Madueno I Cells. 2021; 10(1).

PMID: 33435197 PMC: 7826528. DOI: 10.3390/cells10010119.

IFNβ enhances mesenchymal stromal (Stem) cells immunomodulatory function through STAT1-3 activation and mTOR-associated promotion of glucose metabolism.

Vigo T, La Rocca C, Faicchia D, Procaccini C, Ruggieri M, Salvetti M Cell Death Dis. 2019; 10(2):85.

PMID: 30692524 PMC: 6349843. DOI: 10.1038/s41419-019-1336-4.

References

Martinez-Rodriguez J, Lopez-Botet M, Munteis E, Rio J, Roquer J, Montalban X . Natural killer cell phenotype and clinical response to interferon-beta therapy in multiple sclerosis. Clin Immunol. 2011; 141(3):348-56. DOI: 10.1016/j.clim.2011.09.006. View

KAWADE Y . Quantitation of neutralization of interferon by antibody. Methods Enzymol. 1986; 119:558-73. DOI: 10.1016/0076-6879(86)19076-8. View

Hartung H, Steinman L, Goodin D, Comi G, Cook S, Filippi M . Interleukin 17F level and interferon β response in patients with multiple sclerosis. JAMA Neurol. 2013; 70(8):1017-21. PMC: 4290836. DOI: 10.1001/jamaneurol.2013.192. View

Skulina C, Schmidt S, Dornmair K, Babbe H, Roers A, Rajewsky K . Multiple sclerosis: brain-infiltrating CD8+ T cells persist as clonal expansions in the cerebrospinal fluid and blood. Proc Natl Acad Sci U S A. 2004; 101(8):2428-33. PMC: 356967. DOI: 10.1073/pnas.0308689100. View

Jacobs L, Cookfair D, Rudick R, Herndon R, Richert J, Salazar A . Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol. 1996; 39(3):285-94. DOI: 10.1002/ana.410390304. View

. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet. 1998; 352(9139):1498-504. View

Villar L, Espino M, Roldan E, Marin N, Costa-Frossard L, Muriel A . Increased peripheral blood CD5+ B cells predict earlier conversion to MS in high-risk clinically isolated syndromes. Mult Scler. 2011; 17(6):690-4. DOI: 10.1177/1352458510396922. View

Einarson T, Bereza B, Machado M . Comparative effectiveness of interferons in relapsing-remitting multiple sclerosis: a meta-analysis of real-world studies. Curr Med Res Opin. 2016; 33(3):579-593. DOI: 10.1080/03007995.2016.1276895. View

Bielekova B, Catalfamo M, Reichert-Scrivner S, Packer A, Cerna M, Waldmann T . Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci U S A. 2006; 103(15):5941-6. PMC: 1458677. DOI: 10.1073/pnas.0601335103. View

10.

Garcia-Montojo M, Dominguez-Mozo M, de las Heras V, Bartolome M, Garcia-Martinez A, Arroyo R . Neutralizing antibodies, MxA expression and MMP-9/TIMP-1 ratio as markers of bioavailability of interferon-beta treatment in multiple sclerosis patients: a two-year follow-up study. Eur J Neurol. 2010; 17(3):470-8. DOI: 10.1111/j.1468-1331.2009.02890.x. View

11.

Giovannoni G, Turner B, Gnanapavan S, Offiah C, Schmierer K, Marta M . Is it time to target no evident disease activity (NEDA) in multiple sclerosis?. Mult Scler Relat Disord. 2015; 4(4):329-33. DOI: 10.1016/j.msard.2015.04.006. View

12.

Polman C, Reingold S, Banwell B, Clanet M, Cohen J, Filippi M . Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011; 69(2):292-302. PMC: 3084507. DOI: 10.1002/ana.22366. View

13.

Rio J, Castillo J, Rovira A, Tintore M, Sastre-Garriga J, Horga A . Measures in the first year of therapy predict the response to interferon beta in MS. Mult Scler. 2009; 15(7):848-53. DOI: 10.1177/1352458509104591. View

14.

Pachner A, Dail D, Pak E, Narayan K . The importance of measuring IFNbeta bioactivity: monitoring in MS patients and the effect of anti-IFNbeta antibodies. J Neuroimmunol. 2005; 166(1-2):180-8. DOI: 10.1016/j.jneuroim.2005.06.003. View

15.

Bertolotto A, Sala A, Malucchi S, Marnetto F, Caldano M, Di Sapio A . Biological activity of interferon betas in patients with multiple sclerosis is affected by treatment regimen and neutralising antibodies. J Neurol Neurosurg Psychiatry. 2004; 75(9):1294-9. PMC: 1739245. DOI: 10.1136/jnnp.2004.037259. View

16.

. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology. 1993; 43(4):655-61. DOI: 10.1212/wnl.43.4.655. View

17.

Praksova P, Stourac P, Bednarik J, Vlckova E, Mikulkova Z, Michalek J . Immunoregulatory T cells in multiple sclerosis and the effect of interferon beta and glatiramer acetate treatment on T cell subpopulations. J Neurol Sci. 2012; 319(1-2):18-23. DOI: 10.1016/j.jns.2012.05.036. View

18.

Rotstein D, Healy B, Malik M, Chitnis T, Weiner H . Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort. JAMA Neurol. 2014; 72(2):152-8. DOI: 10.1001/jamaneurol.2014.3537. View

19.

Bushnell S, Zhao Z, Stebbins C, Cadavid D, Buko A, Whalley E . Serum IL-17F does not predict poor response to IM IFNβ-1a in relapsing-remitting MS. Neurology. 2012; 79(6):531-7. PMC: 3413762. DOI: 10.1212/WNL.0b013e318259e123. View

20.

De Mercanti S, Rolla S, Cucci A, Bardina V, Cocco E, Vladic A . Alemtuzumab long-term immunologic effect: Treg suppressor function increases up to 24 months. Neurol Neuroimmunol Neuroinflamm. 2016; 3(1):e194. PMC: 4723135. DOI: 10.1212/NXI.0000000000000194. View